HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Outcome of renal cell carcinoma in patients on dialysis compared to non-dialysis patients.

AbstractPURPOSE:
To investigate the impact of hemodialysis on survival in renal cell carcinoma (RCC) patients.
METHODS:
We studied 388 patients who underwent radical or partial nephrectomy for RCC at Toranomon Hospital from 2005 to 2013. Survival curves were drawn according to the Kaplan-Meier method and compared with the log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression model to assess the prognostic influence of hemodialysis on cancer-specific survival.
RESULT:
Of the 388 patients, 66 were on hemodialysis and 322 were not on dialysis. In the hemodialysis patients, incidental diagnosis of RCC was less frequent than in the non-dialysis patients. In addition, RCC was more likely to be multicentric (41% vs 1.2%), bilateral (14% vs 0.6%), and papillary (18% vs 7%) in hemodialysis patients. Moreover, tumors were smaller, the stage was lower, and the Fuhrman nuclear grade was higher in the patients on hemodialysis. The 5-year cancer-specific survival rate was 82.8% for hemodialysis patients and 93.5% for nondialysis patients. Multivariate analysis indicated that hemodialysis, stage, and Fuhrman nuclear grade were independent prognostic factors for RCC.
CONCLUSIONS:
This study suggested that hemodialysis was an independent prognostic factor for cancer-specific survival in RCC patients, along with the tumor stage and Fuhrman nuclear grade.
AuthorsNoriko Hayami, Yoshifumi Ubara, Toshikazu Okaneya, Takeshi Fujii, Yoji Nagashima, Kenichi Ohashi
JournalSeminars in dialysis (Semin Dial) Vol. 33 Issue 4 Pg. 316-321 (07 2020) ISSN: 1525-139X [Electronic] United States
PMID32557805 (Publication Type: Journal Article)
Copyright© 2020 Wiley Periodicals LLC.
Topics
  • Carcinoma, Renal Cell (pathology, surgery)
  • Humans
  • Kidney Neoplasms (therapy)
  • Neoplasm Staging
  • Nephrectomy
  • Prognosis
  • Renal Dialysis
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: